Dr. Prof. Jia-fu Ji, MD, FACS

Peking University of School of Oncology & Beijing Cancer Hospital, Beijing, China

Dr. Prof. Jia-fu Ji, MD, FACS, received his master degree from Beijing Medical University (now the Peking University Health Science Center) in 1990.

Dr. Ji is the current director of Peking University School of Oncology & Beijing Cancer Hospital, and head of the Department of Gastrointestinal Surgery. He is the chief expert of Gastric Cancer Collaborative Group of China and the director of the Gastric Cancer Research Program under the Chinese Ministry of Education-sponsored Key Laboratory of Carcinogenesis and Translational Research. He is the head of the Surgery Teaching and Research Section and a supervisor for doctoral candidates in Peking University. He also serves as the chairman of the Gastric Cancer Association of Chinese Anti-Cancer Association, director of International Cooperation Department of China Medical Association (CMA), vice chairman of Gastrointestinal Committee of CMA, vice chairman of Expert Committee of Nutritional Therapy for Cancer, member of Biobank Branch, China Medicinal Biotechnology Association, and chairman of Tumor Examination Committee of Cross-straits Medicine Exchange Association. He is a member of American College of Surgeons (ACS), Asian Surgical Association (ASA), academic committee of International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), International Gastric Cancer Association (IGCA), and European Society for Clinical Nutrition and Metabolism (ESPEN). He is a guest professor of surgery of the IASGO Academy in Europe.

Dr. Ji has been the member of the editorial boards of Digestive Surgery, Annals of Surgery (Chinese edition), National Medical Journal of China, Chinese Journal of Gastrointestinal Surgery, Chinese Journal of Practical Surgery and many other Chinese and international academic journals.

Dr. Ji, a well-known expert in gastrointestinal oncological surgery in China, has actively been involved in the standardization of surgical procedures and the development and application of neo-adjuvant chemotherapy for gastric cancer. Dr Ji’s current research focuses on the integrated treatment of gastric cancer and its molecular mechanisms. He is the leading researcher of many domestic and international clinical trials including Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer (CLASSIC), Multicenter Asia Study in Adjuvant Treatment of Colon Cancer with OxaliplaTin/5FU-LV (MASCOT), and Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen (ACCELOX). Up to now he has led and/or participated in 26 clinical and basic scientific research projects including 3 international projects, 9 state-level projects, and 4 sub-state-level projects. He has undertaken many key research projects sponsored by National Key Technology Research and Development Program of the Ministry of Science and Technology of China during the eleventh and twelfth "Five-Year" plan, National "863" Program, National Natural Science Foundation project, Beijing Municipal Science and Technology Committee key projects, and Peking University Human Disease Genetic Research Center projects. He carried out research on gene expression profiling of gastric cancer under the cooperation with Stanford University, during which he successfully established and optimized a tumor tissue repository through the standardized collection and management of specimens.

Dr. Ji has published more than 100 articles in Chinese and international journals, with a sum of impact factors reaching 130.7. He has authored, co-authored, or translated eight books. He has trained over 40 masters, doctors, and post-doctoral fellows.

Dr. Ji has been the recipient of Beijing Municipal Science & Technology Progress Award (Third Class), Ministry of Science and Technology Excellent Academic Article Award, Beijing Federation of Trade Unions Technical Innovation Pacesetter, and CSCO Advanced Worker.

Ashwani K. Singal, MD

Division of Gastroenterology and Hepatology, Avera Transplant Institute, University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA

Dr. Singal is an Associate Professor of Medicine at the University of South Dakota Sanford School of Medicine and Transplant Hepatologist at the Avera TransplantInstitute. In addition, he also directs the hepatology elective course for the senior medical students at the Sanford medical school and is Chief of clinical research affairs at the Avera transplant institute. With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by theAmerican College of Gastroenterology, National Institute of Health, and pharmaceutical industry. He has over 165 original peer reviewed articles in national / international journals and book chapters. With an active executive member of the ACG practice parameters committee, Dr. Singal has developed practice guidelines for alcoholic liver disease and vascular disorders of the liver, and is currently involved in writing the guidelines on nutritional management of patients with cirrhosis. Apart from reviewing research grants and scientific research abstracts for the AGA and the AASLD, Dr. Singal is currently theSecretary of the special interest group on alcoholic liver disease of the AASLD and Chairs its education subcommittee.

Sanjaya Satapathy, MD

Liver Transplantation at the Northshore University Hospital/Northwell Health, Manhasset, NY, USA

Dr. Sanjaya Satapathy graduated from Veer Surendra Sai Medical College of Sambalpur University, India. He completed his Residency in Internal Medicine training at the same college, and then 2 year of Hepatology training at the Post Graduate Institute of Medical Education andResearch at Chandigarh, India. He then moved to New Delhi where he joined G.B.Pant Hospital as a Gastroenterology Fellow under the mentorship Professor ShivSarin. After completion of his training he moved to the United States in 2004.He re-trained in Internal Medicine (New York Medical College), Gastroenterology(North Shore LIJ Hospital, New York), and went on to complete a Transplant Hepatology Fellowship at the Mount Sinai Medical Center at New York. Dr. Satapathy is board certified in Internal Medicine, Gastroenterology, and Transplant Hepatology by the American Board of Internal Medicine. He has also earned a Masters in Epidemiology and Clinical Investigation from the University of Tennessee Health Sciences Center.

He is currently an Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at the Hofstra University, and serving as the Medical Director of Liver Transplantation at the Northshore University Hospital/Northwell Health. Prior to joining Northwell Health, he was Transplant Hepatologist at the Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, Memphis, and served as a Tenured Associate Professor until 2018. He is also a skilled advanced therapeutic endoscopist particularly in ERCP and EUS. Dr. Satapathy’s research focuses on post-transplant outcomes, particularly in patients with NASH, and hepatitis C. He has published more than100 peer reviewed publications.

Dr. Satapathy has received several accolades throughout his career and currently a Fellow of American Society of Gastrointestinal Endoscopy (FASGE), American College of Gastroenterology(FACG), American Gastroenterological Association (AGAF), American Association of the Liver Diseases (FAASLD). Dr. Satapathy served as an Academic Editor of the journal Medicine, Translational Gastroenterology and Hepatology, and reviewer of several international peer reviewed journals including Hepatology, Gastroenterology, Transplantation and LiverTransplantation to name a few. He has served as Member National Affairs committee and the International Affairs committee of the American College of Gastroenterology. He is also spearheading an international collaboration group that aims to study non-alcoholic fatty liver disease that is now considered a global public health crisis and slated to be the lead indication for liver transplantation in the next decade.